Scher Gabrielle, Bente Dennis A, Mears Megan C, Cajimat Maria N B, Schnell Matthias J
Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
NPJ Vaccines. 2023 May 20;8(1):73. doi: 10.1038/s41541-023-00663-5.
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody against the GP38 glycoprotein protected mice against lethal CCHFV challenge. To show that GP38 is required and sufficient for protection against CCHFV, we used three inactivated rhabdoviral-based CCHFV-M vaccines, with or without GP38 in the presence or absence of the other CCHFV glycoproteins. All three vaccines elicited strong antibody responses against the respective CCHFV glycoproteins. However, only vaccines containing GP38 showed protection against CCHFV challenge in mice; vaccines without GP38 were not protective. The results of this study establish the need for GP38 in vaccines targeting CCHFV-M and demonstrate the efficacy of a CCHFV vaccine candidate based on an established vector platform.
克里米亚-刚果出血热病毒（CCHFV）是一种蜱传病毒，可导致人类严重出血性疾病。目前尚无国际上批准的针对人类CCHFV的有效疫苗和治疗方法，因此对其的需求极为迫切。最近，一种针对GP38糖蛋白的单克隆抗体可保护小鼠免受致命的CCHFV攻击。为了证明GP38对于抵抗CCHFV是必需且足够的，我们使用了三种基于灭活弹状病毒的CCHFV-M疫苗，在有或没有其他CCHFV糖蛋白的情况下添加或不添加GP38。所有三种疫苗均引发了针对各自CCHFV糖蛋白的强烈抗体反应。然而，只有含有GP38的疫苗在小鼠中显示出对CCHFV攻击的保护作用；不含GP38的疫苗没有保护作用。本研究结果表明，在针对CCHFV-M的疫苗中需要GP38，并证明了基于既定载体平台的CCHFV候选疫苗的有效性。
